NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

download NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

of 3

Transcript of NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

  • 8/12/2019 NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

    1/3

    Compassionate Care New York | 347.781.5435 voice | [email protected]

    June 5, 2014

    Dear Senator Savino and Assemblyman Gottfried:

    The members of NY Physicians for Compassionate Care are extremely grateful to your

    leadership in sponsoring legislation that would allow patients in need to gain legal access to

    medical cannabis.

    We are aware that some of your colleagues want you to accept restrictions on the smoking of

    marijuana. It might be reasonable, as you have proposed, to limit smoking of the flowers to

    people 21 years of age and over (hopefully with some exceptions for critical need). However, we

    want to give you the scientific arguments to use to counter the medically unsound proposals that

    you:

    1) exclude smoking altogether,2) or that you limit smoking to only a metered-dose vaporizer approach.

    1. Medical basis for including the smoking route for medical cannabis.

    In 1999, the White House-commissioned Institute of Medicine of the National Academy of

    Sciences spent two years reviewing the scientific data then available with respect to potential

    benefits of medical marijuana. The study team found substantial consensus among experts in

    the relevant disciplines on the scientific evidence about potential medical uses of marijuana.

    The study team concluded that, nausea, appetite loss, pain and anxietyall can be mitigated by

    marijuana. The study team did not exclude smoked marijuana from its conclusions, noting

    instead that there are even some limited circumstances in which we recommend

    smoking marijuana for medical use.See Janet E. Joy, Stanley J. Watson, Jr., and John A.Benson, Jr. Marijuana and Medicine: Assessing the Science Base, Division of Neuroscience and

    Behavioral Research, Institute of Medicine (Washington, DC: National Academy Press, 1999).

    In the past ten years, the findings of that report have been corroborated by numerous peer-

    reviewed, randomized, double-blind controlled studies of smoked marijuana published in highly

    respected and credible medical journalsthis despite little federal support for and significant

    federal obstruction of medical marijuana research. These studies prove the safety and efficacy of

    smoked marijuana for chronic, neuropathic pain. The following is a brief sample of such studies

    (each of which used smoking as the method of ingestion):

    Abrams D, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomizedplacebo-controlled trial.Neurology 68 (2007): 515-521.

    Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent Effects of Smoked Cannabison Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers.Anesthesiology 107(2007):785-796.

    Ellis R. et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized,crossover clinical trial.Neuropsychopharmacology 34 (2009): 672680.

    Wilsey B. et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes inneuropathic pain.Journal of Pain 9 (2008): 506-521.

  • 8/12/2019 NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

    2/3

    Compassionate Care New York | 347.781.5435 voice | [email protected]

    Another issue with the non-smoking approaches is that most of them will utilize extractsof the

    cannabis plant, rather than whole plant material.

    The problems:

    Extracts may leave out therapeutically important terpenoids that are needed for the fullmedical cannabis entourage effect produced by whole plant botanical material; and

    Extracts may be too potent for some patients to tolerate, compared to the whole plantbotanical material (this is due in part to the THC becoming more concentrated, and inpart because the terpenoids that strongly modulate the effects of the cannabinoids may

    be reduced or absent from the extract).

    2. The medical and socioeconomic reasons to not limit smoking toonly a

    metered-dose vaporizer device (vape) approach

    (a)Medical objections to the metered-dose vape approach: One of the bases for this proposal is the assumption(proven incorrect) that medical

    cannabis causes emphysema and/or airway tract cancers. Both assumptions havebeen disproven by clinical studies published in the peer-reviewed literature (seereferences below).

    The companies that process the plant material for these metered-dose devices willfind it in their economic interest to limit the number of strains of cannabis to just afew select strains that they arbitrarily select. It is highly unlikely that they wouldmake available the scores of strains that are needed for the different cannabis-responsive diseases, because they will have toprocesseach of those strains andthat will cut into profits. This would make it impossible for patients to gain legal

    access to the types of strains that theyneed, be it one of scores of subtypes of thesativa and/or indica varietals that are found to be effective. Physicians and patientsshould be the ones deciding on what strains to use not private companies.

    At least one of the private companies that we are aware of, in this vape sector, hasproposed that the cannabis material be irradiated - so as to inactivate any pathogens(molds, fungi, etc.) growing on the plants. Irradiation causes DNA in the cells toclump into what is called adducts, some of which can be carcinogenic. That is why

    we can tell you, as physicians, that this is an unproven long-term safety paradigm.

    (b)Socioeconomic objections to the metered-dose vape approach:The companies and the elected officials who have proposed this approach are clearly not

    taking into account the many thousands of patients in New York who are of limitedfinancial means, and cannot afford either (i) the vape pens themselves (which would

    probably cost a few hundred dollars) or (ii) the metered-dose ampules containing the

    cannabis bud material. It is axiomatic that whenever companies process a product,

    they have to charge more for the processed product than for the unprocessed product.

    Therefore, what would be an excellent business model for these private companies,

    would turn out to be horrendous (and unfair) for patients with fatal or debilitating

    diseases who happen to be of limited means (because of being working poor, because

  • 8/12/2019 NY Physicians for Comp Care - Letter About Smoking - 06 05 2014

    3/3

    Compassionate Care New York | 347.781.5435 voice | [email protected]

    their disease has left them unable to work, or because of medical bankruptcy from the

    costs of their or their childs illness). These people will not be able to afford either the

    processed product or the devices for using it and they will be forced to either go to the

    black market and risk being arrested, or to suffer needlessly.

    In conclusion, the proposals to exclude smoking altogether or to limit smoking to metered-dose

    vaporizer devices run counter to the sound medical practices that have been recognized and

    promulgated by this nations highest scientific bodyThe Institute of Medicine of the National

    Academy of Sciences.

    We hope that this medical information will give you some sound arguments to make to your

    colleagues, to counter their push for compromises that do not have a sound medicalbasis.

    References on the absenceof an association for emphysema and/or cancer in chronic marijuana

    smokers:

    M. Pletcher, E. Vittinghoff, R. Kalhan, et al., (2012)Association Between MarijuanaExposure and Pulmonary Function Over 20 Years," JAMA, 307(2):173-18. Russo, E., Mathre, ML., Byrne, A., Velin, R., Bach, P., Sanchez-Ramos, J., and Kirlin,

    KA. (2002). Chronic Cannabis Use in the Compassionate Investigational New DrugProgram: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis.Journal of Cannabis Therapeutics (JCT): 2(1): 3-57.

    Tashkin et al. Marijuana Use and the Risk of Lung and Upper Aerodigestive TractCancers: Results of a Population-Based Case-Control Study. Cancer Epidemiology,

    Biomarkers & Prevention (2006).

    Bloom JW, et al.Respiratory effects of non-tobacco cigarettes.Br Med J (Clin ResEd). 1987 Dec 12;295(6612):1516-8.

    Aldington S, et al.Effects of cannabis on pulmonary structure, function andsymptoms. Thorax. 2007 Dec;62(12):1058-63.

    Chair, Howard Grossman, MD

    Co-Chair, Sunil Aggarwal, MD, PhD

    New York Physicians for Compassionate Care

    Member, Richard M. Carlton, MD

    NY Physicians for Compassionate Care is group of more than 600 physicians from across New Yorkwho support the use of medical marijuana to alleviate the suffering of patients living with serious illnessor debilitating conditions.

    http://www.ncbi.nlm.nih.gov/pubmed/3122882http://www.ncbi.nlm.nih.gov/pubmed/3122882http://www.ncbi.nlm.nih.gov/pubmed/17666437http://www.ncbi.nlm.nih.gov/pubmed/17666437http://www.ncbi.nlm.nih.gov/pubmed/17666437http://www.ncbi.nlm.nih.gov/pubmed/17666437http://www.ncbi.nlm.nih.gov/pubmed/3122882